Literature DB >> 33170301

Systematic Literature Review and Network Meta-analysis of the Efficacy and Acceptability of Interventions in Actinic Keratoses.

Khaled Ezzedine1, Caroline Painchault, Melanie Brignone.   

Abstract

A systematic literature review was conducted to identify and qualitatively assess randomized controlled trials in immunocompetent patients ≥ 18 years with head- region lesions of actinic keratoses who were treated with field-directed, lesion-directed and other therapies. Network meta-analysis was used to quantitatively evaluate field-directed therapies (5-fluorouracil formulations, diclofenac sodium, imiquimod, ingenol mebutate, 5-aminolevulinic acid or methyl aminolevulinate plus photodynamic therapy) using complete clearance or partial clearance of actinic keratoses lesions, and adverse event-related withdrawals as a proxy of acceptability. Of 2,863 references identified, 75 trials reported in 151 publications were included. In summary, comparative network meta-analysis evaluation showed that 5-fluorouracil formulations were the most efficacious interventions examined. 5-fluorouracil 4%, which was recently approved, showed a comparable efficacy profile to 5-fluorouracil 5%, and had satisfactory acceptability outcomes.

Entities:  

Keywords:  field-directed intervention; network meta-analysis; systematic literature review; actinic keratosis

Mesh:

Substances:

Year:  2021        PMID: 33170301      PMCID: PMC9309865          DOI: 10.2340/00015555-3690

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   3.875


  39 in total

1.  Low-dose 5-fluorouracil in combination with salicylic acid as a new lesion-directed option to treat topically actinic keratoses: histological and clinical study results.

Authors:  E Stockfleth; H Kerl; T Zwingers; C Willers
Journal:  Br J Dermatol       Date:  2011-11       Impact factor: 9.302

2.  Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp.

Authors:  Emil Tanghetti; Philip Werschler
Journal:  J Drugs Dermatol       Date:  2007-02       Impact factor: 2.114

3.  Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment.

Authors:  Jean-Paul Ortonne; Girish Gupta; Nicolas Ortonne; Luc Duteil; Catherine Queille; Pascal Mallefet
Journal:  Exp Dermatol       Date:  2010-02-25       Impact factor: 3.960

4.  Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study.

Authors:  R-M Szeimies; P Radny; M Sebastian; F Borrosch; T Dirschka; G Krähn-Senftleben; K Reich; G Pabst; D Voss; M Foguet; R Gahlmann; H Lübbert; U Reinhold
Journal:  Br J Dermatol       Date:  2010-05-28       Impact factor: 9.302

5.  Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes.

Authors:  Matthias Augustin; John H Tu; Kim Mark Knudsen; Sandra Erntoft; Thomas Larsson; C William Hanke
Journal:  J Am Acad Dermatol       Date:  2015-03-11       Impact factor: 11.527

Review 6.  Network meta-analysis of the outcome 'participant complete clearance' in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review.

Authors:  A K Gupta; M Paquet
Journal:  Br J Dermatol       Date:  2013-08       Impact factor: 9.302

7.  Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.

Authors:  Joseph Jorizzo; Scott Dinehart; Robert Matheson; Jeffrey K Moore; Mark Ling; Terry L Fox; Scott McRae; Sandra Fielder; James H Lee
Journal:  J Am Acad Dermatol       Date:  2007-05-18       Impact factor: 11.527

8.  Effective photodynamic therapy of actinic keratoses on the head and face with a novel, self-adhesive 5-aminolaevulinic acid patch.

Authors:  Axel Hauschild; Georg Popp; Eggert Stockfleth; Karl-Gustav Meyer; Dirk Imberger; Peter Mohr; Götz Itschert; Roland Kaufmann; Karsten Neuber; Yvonne Frambach; Harald Gollnick; Marcus Brunnert; Marcus Stocker; Christoph Ortland; Sigrid Karrer
Journal:  Exp Dermatol       Date:  2008-07-17       Impact factor: 3.960

9.  Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head.

Authors:  A Alomar; J Bichel; S McRae
Journal:  Br J Dermatol       Date:  2007-06-15       Impact factor: 9.302

10.  Risk factors for actinic keratosis in eight European centres: a case-control study.

Authors:  A Traianou; M Ulrich; Z Apalla; E De Vries; K Bakirtzi; D Kalabalikis; L Ferrandiz; A Ruiz-de-Casas; D Moreno-Ramirez; D Sotiriadis; D Ioannides; S Aquilina; C Apap; R Micallef; L Scerri; S Pitkänen; O Saksela; E Altsitsiadis; B Hinrichs; C Magnoni; C Fiorentini; S Majewski; A Ranki; C M Proby; E Stockfleth; M Trakatelli
Journal:  Br J Dermatol       Date:  2012-08       Impact factor: 9.302

View more
  3 in total

1.  Topical Photodynamic Therapy with Different Forms of 5-Aminolevulinic Acid in the Treatment of Actinic Keratosis.

Authors:  Joanna Bartosińska; Paulina Szczepanik-Kułak; Dorota Raczkiewicz; Marta Niewiedzioł; Agnieszka Gerkowicz; Dorota Kowalczuk; Mirosław Kwaśny; Dorota Krasowska
Journal:  Pharmaceutics       Date:  2022-02-01       Impact factor: 6.321

Review 2.  Topical Pharmacotherapy for Actinic Keratoses in Older Adults.

Authors:  Piergiacomo Calzavara-Pinton; Irene Calzavara-Pinton; Chiara Rovati; Mariateresa Rossi
Journal:  Drugs Aging       Date:  2022-02-14       Impact factor: 3.923

3.  Comparative Efficacy and Safety of Tirbanibulin for Actinic Keratosis of the Face and Scalp in Europe: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Markus V Heppt; Igor Dykukha; Sara Graziadio; Rafael Salido-Vallejo; Matt Chapman-Rounds; Mary Edwards
Journal:  J Clin Med       Date:  2022-03-16       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.